Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution

References

• Atyabi, F., Farkhondehfai, A., Esmaeili, F., Dinarvand, R. (2009). Preparation of pegylated nano-liposomal formulation containing SN-38: in vitro characterization and in vivo biodistribution in mice. Acta Pharm 59:133–144.
   PubMed Web of Science ®Google Scholar
• Awasthi, V., Goins, B., Klipper, R., Loredo, R., Korvick, D., Phillips, W. T. (1998). Imaging experimental osteomyelitis using radiolabeled liposomes. J Nucl Med 39:1089–1094.
   PubMedGoogle Scholar
• Awasthi, V. D., Goins, B., Klipper, R., Phillips, W. T. (2002). Accumulation of PEG-liposomes in the inflamed colon of rats: potential for therapeutic and diagnostic targeting of inflammatory bowel diseases. J Drug Target 10:419–427.
   PubMed Web of Science ®Google Scholar
• Bao, A., Goins, B., Klipper, R., Negrete, G., Phillips, W. T. (2004). Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J Pharmacol Exp Ther 308:419–425.
   PubMed Web of Science ®Google Scholar
• Berrada, M., Serreqi, A., Dabbarh, F., Owusu, A., Gupta, A., Lehnert, S. (2005). A novel non-toxic camptothecin formulation for cancer chemotherapy. Biomaterials 26:2115–2120.
   PubMed Web of Science ®Google Scholar
• Bom, D., Curran, D. P., Kruszewski, S., Zimmer, S. G., Thompson Strode, J., Kohlhagen, G., et al. (2000). The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 43:3970–3980.
   PubMed Web of Science ®Google Scholar
• Bom, D., Curran, D. P., Zhang, J., Zimmer, S. G., Bevins, R., Kruszewski, S., et al. (2001). The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Release 74:325–333.
   PubMedGoogle Scholar
• Bordi, F., Cametti, C., Sennato, S., Diociaiuti, M. (2006). Direct evidence of multicompartment aggregates in polyelectrolyte-charged liposome complexes. Biophys J 91:1513–1520.
   PubMed Web of Science ®Google Scholar
• Brandl, M. (2001). Liposomes as drug carriers: a technological approach. Biotechnol Annu Rev 7:59–85.
   PubMedGoogle Scholar
• Brandl, M. (2003). Liposomal drug carriers for cancer diagnosis and therapy. In: Budman, D. R., Calvert, A. H., Rowinsky, E. K. (Eds.), Handbook of anticancer drug development (pp. 225–236). Philadelphia, Pennsylvania, USA: Lippincott Williams & Wilkins.
   Google Scholar
• Burke, T. G. (1996). Liposomal and micellar stabilization of camptothecin drugs. U.S. patent application 5,552,156.
   Google Scholar
• Burke, T. G., Bom, D. (2000). Camptothecin design and delivery approaches for elevating anti-topoisomerase I activities in vivo. Ann N Y Acad Sci 922:36–45.
   PubMed Web of Science ®Google Scholar
• Burke, T. G., Gao, X. (1994). Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J Pharm Sci 83:967–969.
   PubMed Web of Science ®Google Scholar
• Burke, T. G., Mishra, A. K., Wani, M. C., Wall, M. E. (1993). Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 32:5352–5364.
   PubMed Web of Science ®Google Scholar
• Burke, T. G., Staubus, A. E., Mishra, A. K., Malak, H. (1992). Liposomal stabilization of camptothecins lactone ring. J Am Chem Soc 114:8318–8319.
   Web of Science ®Google Scholar
• Chen, J., Cai, B., Ping, Q., Liu, M., Guo, J. (2008). Lactone stability and tissue distribution of free and liposomal encapsulated 9-nitrocamptothecin in rats following intravenous injection. Drug Dev Ind Pharm 34:853–859.
   PubMed Web of Science ®Google Scholar
• Chen, J., Ping, Q. N., Guo, J. X., Chu, X. Z., Song, M. M. (2006). Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin. Drug Dev Ind Pharm 32:719–726.
   PubMed Web of Science ®Google Scholar
• Chonn, A., Semple, S. C., Cullis, P. R. (1991). Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma-proteins which mediate liposome clearance in vivo. Biochim Biophys Acta 1070:215–222.
   PubMed Web of Science ®Google Scholar
• Chou, T. H., Chen, S. C., Chu, I. M. (2003). Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method. J Biosci Bioeng 95:405–408.
   PubMed Web of Science ®Google Scholar
• Clements, M. K., Wasi, S., Daoud, S. S. (1996). Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells in vitro. Anticancer Drugs 7:851–857.
   PubMed Web of Science ®Google Scholar
• Colbern, G. T., Dykes, D. J., Engbers, C., Musterer, R., Hiller, A., Pegg, E., et al. (1998). Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin Cancer Res 4:3077–3082.
   PubMed Web of Science ®Google Scholar
• Dadashzadeh, S., Vali, A. M., Rezaie, M. (2008). The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Int J Pharm 353:251–259.
   PubMed Web of Science ®Google Scholar
• Daoud, S. S., Fetouh, M. I., Giovanella, B. C. (1995). Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts. Anticancer Drugs 6:83–93.
   PubMed Web of Science ®Google Scholar
• Desjardins, J. P., Abbott, E. A., Emerson, D. L., Tomkinson, B. E., Leray, J. D., Brown, E. N., et al. (2001). Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice. Anticancer Drugs 12:235–245.
   PubMedGoogle Scholar
• Drummond, D. C., Noble, C. O., Guo, Z., Hayes, M. E., Connolly-Ingram, C., Gabriel, B. S., et al. (2010). Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Rel 141:13–21.
   PubMed Web of Science ®Google Scholar
• Drummond, D. C., Noble, C. O., Guo, Z., Hong, K., Park, J. W., Kirpotin, D. B. (2006). Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 66:3271–3277.
   PubMed Web of Science ®Google Scholar
• Eichhorn, M. E., Luedemann, S., Strieth, S., Papyan, A., Ruhstorfer, H., Haas, H., et al. (2007). Cationic lipid complexed camptothecin (EndoTAG-2) improves antitumoral efficacy by tumor vascular targeting. Cancer Biol Ther 6:920–929.
   PubMed Web of Science ®Google Scholar
• ElBayoumi, T. A., Torchilin, V. P. (2009). Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 15:1973–1980.
   PubMed Web of Science ®Google Scholar
• Emerson, D. L. (2000). Liposomal delivery of camptothecins. Pharm Sci Technolo Today 3:205–209.
   PubMedGoogle Scholar
• Emerson, D. L., Bendele, R., Brown, E., Chiang, S., Desjardins, J. P., Dihel, L. C., et al. (2000). Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clin Cancer Res 6:2903–2912.
   PubMed Web of Science ®Google Scholar
• Fahr, A., Van Hoogevest, P., Kuntsche, J., Leigh, M. L. S. (2006). Lipophilic drug transfer between liposomal and biological membranes: What does it mean for parenteral and oral drug delivery? J Liposome Res 16:281–301.
   PubMed Web of Science ®Google Scholar
• Forssen, E. A., Ross, M. E. (1994). Daunoxome® treatment of solid tumors: preclinical and clinical investigations. J Liposome Res 4:481–512.
   Google Scholar
• Garcia-Carbonero, R., Supko, J. G. (2002). Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641–661.
   PubMed Web of Science ®Google Scholar
• Gilbert, B. E., Seryshev, A., Knight, V., Brayton, C. (2002). 9-nitrocamptothecin liposome aerosol: lack of subacute toxicity in dogs. Inhal Toxicol 14:185–197.
   PubMed Web of Science ®Google Scholar
• Goins, B., Klipper, R., Rudolph, A. S., Phillips, W. T. (1994). Use of technetium-99m-liposomes in tumor imaging. J Nucl Med 35:1491–1498.
   PubMed Web of Science ®Google Scholar
• Goins, B., Phillips, W. T. (2003). Radiolabelled liposomes for imaging and biodistribution studies. In: Torchilin, V. P., Wessig, V. (Eds.), Liposomes, 2nd ed. (pp. 319–336). New York: Oxford University Press.
   Google Scholar
• Grohganz, H., Ziroli, V., Massing, U., Brandl, M. (2003). Quantification of various phosphatidylcholines in liposomes by enzymatic assay. AAPS Pharm Sci Tech 4:E63.
   PubMedGoogle Scholar
• Gurung, P., Young, B. M., Coleman, R. A., Wiechert, S., Turner, L. E., Ray, N. B., et al. (2009). Chronic ethanol induces inhibition of antigen-specific CD8+ but not CD4+ immunodominant T cell responses following Listeria monocytogenes inoculation. J Leuk Biol 85:34–43.
   PubMedGoogle Scholar
• Hatefi, A., Amsden, B. (2002). Camptothecin delivery methods. Pharm Res 19:1389–1399.
   PubMed Web of Science ®Google Scholar
• Hattori, Y., Shi, L., Ding, W., Koga, K., Kawano, K., Hakoshima, M., et al. (2009). Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J Control Releas 136:30–37.
   PubMed Web of Science ®Google Scholar
• Kawano, K., Watanabe, M., Yamamoto, T., Yokoyama, M., Opanasopit, P., Okano, T., et al. (2006). Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J Control Release 112:329–332.
   PubMed Web of Science ®Google Scholar
• Kelly, C., Jefferies, C., Cryan, S. A. (2011). Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv 2011:727241.
   PubMedGoogle Scholar
• Koshkina, N. V., Gilbert, B. E., Waldrep, J. C., Seryshev, A., Knight, V. (1999). Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharmacol 44:187–192.
   PubMed Web of Science ®Google Scholar
• Kruszewski, S., Burke, T. G. (2002). Camptothecins affinity to HSA and membranes determined by fluorescence anisotropy measurements. Optica Applicata 32:721–730.
   Google Scholar
• Lei, S, Chien, P. Y., Sheikh, S, Zhang, A, Ali, S, Ahmad, I (2004). Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice. Anticancer Drugs 15: 773–778.
   PubMed Web of Science ®Google Scholar
• Li, X., Hirsh, D. J., Cabral-Lilly, D., Zirkel, A., Gruner, S. M., Janoff, A. S., et al. (1998). Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta 1415:23–40.
   PubMed Web of Science ®Google Scholar
• Liu, J. J., Hong, R. L., Cheng, W. F., Hong, K., Chang, F. H., Tseng, Y. L. (2002). Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation. Anticancer Drugs 13:709–717.
   PubMed Web of Science ®Google Scholar
• Loos, W. J., Kehrer, D., Brouwer, E., Verweij, J., De Bruijn, P., Hamilton, M., et al. (2000). Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 738:155–163.
   PubMedGoogle Scholar
• MacKenzie, M. J., Hirte, H. W., Siu, L. L., Gelmon, K., Ptaszynski, M., Fisher, B., et al. (2004). A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Ann Oncol 15:665–670.
   PubMed Web of Science ®Google Scholar
• Maitani, Y., Katayama, S., Kawano, K., Hayama, A., Toma, K. (2008). Artificial lipids stabilized camptothecin incorporated in liposomes. Biol Pharm Bull 31:990–993.
   PubMed Web of Science ®Google Scholar
• Matsumura, Y., Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392.
   PubMed Web of Science ®Google Scholar
• Mi, Z., Burke, T. G. (1994). Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33:10325–10336.
   PubMed Web of Science ®Google Scholar
• Min, K. H., Park, K., Kim, Y. S., Bae, S. M., Lee, S., Jo, H. G., et al. (2008). Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Control Release 127:208–218.
   PubMed Web of Science ®Google Scholar
• Mougin-Degraef, M., Bourdeau, C., Jestin, E., Sai-Maurel, C., Bourgeois, A., Remaud-Le Saec, P., et al. (2007). Doubly radiolabeled liposomes for pretargeted radioimmunotherapy. Int J Pharm 344:110–117.
   PubMedGoogle Scholar
• Ogihara, I., Kojima, S., Jay, M. (1986). Differential uptake of gallium-67-labeled liposomes between tumors and inflammatory lesions in rats. J Nucl Med 27:1300–1307.
   PubMed Web of Science ®Google Scholar
• Ogiso, T., Niinaka, N., Iwaki, M. (1996). Mechanism for enhancement effect of lipid disperse system on percutaneous absorption. J Pharm Sci 85:57–64.
   PubMed Web of Science ®Google Scholar
• Perez-Soler, R., Sugarman, S. M., Poirot, K. R. (1998). Lipid complexed topoisomerase I inhibitors. U.S. patent application 5,834,012.
   Google Scholar
• Phillips, W. T., Goins, B. (2002). Assessment of liposome delivery using scintigraphic imaging. J Liposome Res 12:71–80.
   PubMed Web of Science ®Google Scholar
• Phillips, W. T., Goins, B. A., Bao, A. (2009). Radioactive liposomes. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:69–83.
   PubMed Web of Science ®Google Scholar
• Proulx, M. E., Desormeaux, A., Marquis, J. F., Olivier, M., Bergeron, M. G. (2001). Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob Agents Chemother 45:2623–2627.
   PubMed Web of Science ®Google Scholar
• Sadzuka, Y. (2000). Effective prodrug liposome and conversion to active metabolite. Curr Drug Metab 1:31–48.
   PubMedGoogle Scholar
• Sadzuka, Y., Hirota, S. (1997). Effect of CPT-11 on lipid peroxide level in mouse tissues. Jpn J Cancer Res 88:512–516.
   PubMedGoogle Scholar
• Sadzuka, Y., Hirotsu, S., Hirota, S. (1998). Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett 127:99–106.
   PubMed Web of Science ®Google Scholar
• Sadzuka, Y., Hirotsu, S., Hirota, S. (1999). Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38. Jpn J Cancer Res 90:226–232.
   PubMedGoogle Scholar
• Sadzuka, Y., Takabe, H., Sonobe, T. (2005). Liposomalization of SN-38 as active metabolite of CPT-11. J Control Release 108:453–459.
   PubMed Web of Science ®Google Scholar
• Saetern, A. M., Brandl, M., Bakkelund, W. H., Sveinbjornsson, B. (2004a). Cytotoxic effect of different camptothecin formulations on human colon carcinoma in vitro. Anticancer Drugs 15:899–906.
   PubMed Web of Science ®Google Scholar
• Saetern, A. M., Flaten, G. E., Brandl, M. (2004b). A method to determine the incorporation capacity of camptothecin in liposomes. AAPS Pharm Sci Tech 5:e40.
   PubMedGoogle Scholar
• Senmaru, N., Shichinohe, T., Takeuchi, M., Miyamoto, M., Sazawa, A., Ogiso, Y., et al. (1998). Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y. Int J Cancer 78:366–371.
   PubMedGoogle Scholar
• Sou, K., Goins, B., Leland, M. M., Tsuchida, E., Phillips, W. T. (2010). Bone marrow-targeted liposomal carriers: a feasibility study in nonhuman primates. Nanomedicine (Lond) 5:41–49.
   PubMed Web of Science ®Google Scholar
• Stella, V. J., Rajewski, R. A. (1997). Cyclodextrins: their future in drug formulation and delivery. Pharm Res 14:556–567.
   PubMed Web of Science ®Google Scholar
• Subramanian, D., Muller, M. T. (1995). Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan. Oncol Res 7:461–469.
   PubMed Web of Science ®Google Scholar
• Sugarman, S. M., Zou, Y. Y., Wasan, K., Poirot, K., Kumi, R., Reddy, S., et al. (1996). Lipid complexed camptothecin: Formulation and initial biodistribution and antitumor activity studies. Cancer Chemother Pharmacol 37:531–538.
   PubMed Web of Science ®Google Scholar
• Tardi, P., Choice, E., Masin, D., Redelmeier, T., Bally, M., Madden, T. D. (2000). Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60:3389–3393.
   PubMed Web of Science ®Google Scholar
• Tomayko, M. M., Reynolds, C. P. (1989). Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24:148–154.
   PubMed Web of Science ®Google Scholar
• Torchilin, V. P., Weissig, V. (2003). Liposomes. Oxford, UK: Oxford University Press.
   Google Scholar
• Watanabe, M., Kawano, K., Toma, K., Hattori, Y., Maitani, Y. (2008). In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. J. Control Release 127:231–238.
   PubMed Web of Science ®Google Scholar
• Watanabe, M., Kawano, K., Yokoyama, M., Opanasopit, P., Okano, T., Maitani, Y. (2006). Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability. Int J Pharm 308:183–189.
   PubMed Web of Science ®Google Scholar
• Wilson, K. D., Raney, S. G., Sekirov, L., Chikh, G., Dejong, S. D., Cullis, P. R., Tam, Y. K. (2007). Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake, and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int Immunopharmacol 7:1064–1075.
   PubMed Web of Science ®Google Scholar
• Yang, S. C., Lu, L. F., Cai, Y., Zhu, J. B., Liang, B. W., Yang, C. Z. (1999). Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 59:299–307.
   PubMed Web of Science ®Google Scholar
• Yang, Y., Ma, Y., Wang, S. (2012). A novel method to load topotecan into liposomes driven by a transmembrane NH(4)EDTA gradient. Eur J Pharm Biopharm 80:332–339.
   PubMed Web of Science ®Google Scholar
• Zhang, J. A., Xuan, T., Parmar, M., Ma, L., Ugwu, S., Ali, S., et al. (2004). Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm 270:93–107.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., Yao, J. (2012). Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity. AAPS PharmSciTech 13:802–810.
   PubMed Web of Science ®Google Scholar
• Zucker, D., Andriyanov, A. V., Steiner, A., Raviv, U., Barenholz, Y. (2012). Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. J Control Release 160:281–289.
   PubMed Web of Science ®Google Scholar